North America Endoscopic Retrograde Cholangiopancreatography Devices Market, By Product Type (Endotherapy Devices, Endoscopes, Imaging Devices, and Others), Modality (Single Use, Standalone, Handheld), Procedure (Biliary Sphicterectomy, Biliary Stenting, Biliary Dilation, Pancreatic Duct Stenting, Pancreatic Sphicterectomy), Application (Bile Duct, Pancreas, Gall Bladder, Liver and Others), End User(Hospitals, Ambulatory Surgical Center, Diagnostic Laboratories and Others), Facility Type (Large, Medium and Small), Distribution Channel (Direct Tenders, Third Party Distribution, and Retail Sales), Country (U.S., Canada, and Mexico) Industry Trends and Forecast 2028.
Market Analysis and Insights: North America Endoscopic Retrograde Cholangiopancreatography Devices Market
North America endoscopic retrograde cholangiopancreatography devices market is expected to grow in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2021 to 2028 and is expected to reach USD 1,179.01 million by 2028 from USD 767.59 million in 2020. The high prevalence of pancreatic and biliary diseases is likely to be the major drivers that propel the market's demand in the forecast period.
The high prevalence of pancreatic and biliary diseases, presence of large number of players in the market and development of advanced technology based devices are driving the growth of the market. The stringent regulatory scenario set by FDA is acting as restraint for the market. The advanced healthcare infrastructure, favourable reimbursement scenario is acting as opportunity for the market. However, the shortage of skilled personnel may act as a challenge for the market growth.
The North America endoscopic retrograde cholangiopancreatography devices market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
North America Endoscopic Retrograde Cholangiopancreatography Devices Market Scope and Market Size
North America endoscopic retrograde cholangiopancreatography devices market is categorized into seven notable segments which are based on product type, modality, procedure, application, end user, facility type, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the North America endoscopic retrograde cholangiopancreatography devices market is segmented into endotherapy devices, endoscopes, imaging devices, and others. In 2021, the endotherapy devices segment is expected to dominate the market due to various types of equipment, and big players are manufacturing this equipment in the North American market.
- On the basis of modality, the North America endoscopic retrograde cholangiopancreatography devices market is segmented into single-use, standalone, and handheld. In 2021, the single-use segment is expected to dominate the market because there is no risk of disease transmission from one patient to another while using single-use devices.
- On the basis of procedure, the North America endoscopic retrograde cholangiopancreatography devices market is segmented into biliary sphincterotomy, biliary stenting, biliary dilation, pancreatic duct stenting, and pancreatic sphincterotomy. In 2021, the biliary sphincterotomy segment is expected to dominate the market because of the high prevalence of pancreatic tumors in the North American region.
- On the basis of application, the North America endoscopic retrograde cholangiopancreatography devices market is segmented into the bile duct, pancreas, gall bladder, liver, and others. In 2021, the bile duct segment is expected to dominate the market because of the high prevalence of biliary diseases in the North American region.
- On the basis of end user, the North America endoscopic retrograde cholangiopancreatography devices market is segmented into hospitals, ambulatory surgical centers, diagnostic laboratories, and others. In 2021, the hospital's segment is expected to dominate the market due to the growing emphasis on strategic initiatives (such as acquisitions, partnerships, and collaborations) by medical device companies to expand their capabilities in the ERCP market.
- On the basis of facility type, the North America endoscopic retrograde cholangiopancreatography devices market is segmented into large, medium, and small. In 2021, the large segment is expected to dominate the market due to the high demand for ERCP procedures in North America.
- On the basis of distribution channel, the North America endoscopic retrograde cholangiopancreatography devices market is segmented into direct tenders, third-party distribution, and retail sales. In 2021, the direct tender segment is expected to dominate the market because of significant growth due to the overall control over sales and revenue processes and direct interactions with customers.
North America Endoscopic Retrograde Cholangiopancreatography Devices Market Country Level Analysis
The North America endoscopic retrograde cholangiopancreatography devices market is analyzed, and market size information is provided by country, product type, modality, procedure, applications, end-user, facility type, and distribution channel.
The countries covered in the North America endoscopic retrograde cholangiopancreatography devices market report are the U.S., Canada, and Mexico.
North America is expected to dominate the market as in the North American countries; the demand for ERCP devices is increasing rapidly with increasing healthcare infrastructure. The U.S. is expected to dominate in the North American market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the North America Endoscopic Retrograde Cholangiopancreatography Devices Market
North America endoscopic retrograde cholangiopancreatography devices market also provides you with detailed market analysis for every country's growth in a particular industry with ERCP products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the market. The data is available for the historical period 2010 to 2019.
Competitive Landscape and Europe Endoscopic Retrograde Cholangiopancreatography Devices Market Share Analysis
North America endoscopic retrograde cholangiopancreatography devices market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company's focus on the endoscopic retrograde cholangiopancreatography devices market.
The major companies providing the North America endoscopic retrograde cholangiopancreatography devices are Olympus Corporation, Boston Scientific Corporation, Medtronic, BD, Ambu Inc., CONMED Corporation, HOBBS MEDICAL, INC., FUJIFILM Corporation, TeleMed Systems, Inc., Merit Medical Systems, Cook, KARL STORZ SE & Co. KG, Johnson & Johnson Services, Inc., HOYA Corporation, STERIS, Shaili Endoscopy, among others.
DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players and new technological advancements for endoscopic retrograde cholangiopancreatography devices are bridging the gap for various treatments.
For instance,
- In July 2020, Ambu Inc. announced that it has received FDA approval for sterile, single use duodenoscope, Ambu aScope Duodeno. This has helped the company to expand its business in coming years.
- In January 2021, CONMED Corporation to present at the J.P. Morgan Virtual Healthcare Conference. The conference aimed at furnishing correct knowledge about its products to customers. This conference has boosted the market growth and aids in revenue generation.
Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the endoscopic retrograde cholangiopancreatography devices market, which also benefits the organization to improve their offering for the market.
SKU-